Wall Street analysts forecast that Five Prime Therapeutics, Inc. (NASDAQ:FPRX) will report earnings per share (EPS) of ($1.29) for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Five Prime Therapeutics’ earnings, with estimates ranging from ($1.51) to ($1.04). Five Prime Therapeutics posted earnings per share of ($0.73) in the same quarter last year, which indicates a negative year-over-year growth rate of 76.7%. The business is expected to report its next earnings results on Thursday, February 22nd.
On average, analysts expect that Five Prime Therapeutics will report full year earnings of ($5.56) per share for the current fiscal year, with EPS estimates ranging from ($5.84) to ($5.38). For the next financial year, analysts expect that the company will report earnings of ($5.59) per share, with EPS estimates ranging from ($6.65) to ($3.52). Zacks’ earnings per share calculations are a mean average based on a survey of research firms that that provide coverage for Five Prime Therapeutics.
Five Prime Therapeutics (NASDAQ:FPRX) last issued its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($1.54) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.35) by ($0.19). Five Prime Therapeutics had a negative return on equity of 41.57% and a negative net margin of 408.42%. The firm had revenue of $8.33 million for the quarter, compared to analyst estimates of $16.16 million. During the same period in the prior year, the firm posted ($0.72) EPS. The business’s revenue was up 24.7% compared to the same quarter last year.
A number of brokerages have commented on FPRX. ValuEngine cut Five Prime Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, November 7th. Zacks Investment Research cut Five Prime Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. BMO Capital Markets lifted their price target on Five Prime Therapeutics from $71.00 to $75.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 7th. Jefferies Group reaffirmed a “buy” rating and set a $52.00 price target on shares of Five Prime Therapeutics in a research report on Tuesday, September 12th. Finally, Royal Bank Of Canada reaffirmed a “buy” rating and set a $41.00 price target on shares of Five Prime Therapeutics in a research report on Wednesday, October 25th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $64.00.
In related news, Director William R. Ringo sold 600 shares of the company’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $45.33, for a total value of $27,198.00. Following the completion of the transaction, the director now owns 600 shares of the company’s stock, valued at approximately $27,198. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director William R. Ringo sold 1,800 shares of the company’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $40.26, for a total value of $72,468.00. Following the completion of the transaction, the director now directly owns 1,200 shares of the company’s stock, valued at approximately $48,312. The disclosure for this sale can be found here. In the last three months, insiders sold 4,400 shares of company stock valued at $175,666. Insiders own 6.50% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Oppenheimer & Co. Inc. acquired a new position in Five Prime Therapeutics in the 3rd quarter worth about $223,000. Creative Planning increased its stake in Five Prime Therapeutics by 0.8% during the 2nd quarter. Creative Planning now owns 6,744 shares of the biotechnology company’s stock worth $203,000 after buying an additional 54 shares in the last quarter. Dupont Capital Management Corp purchased a new stake in Five Prime Therapeutics during the 3rd quarter worth approximately $341,000. Legal & General Group Plc increased its stake in Five Prime Therapeutics by 39.2% during the 1st quarter. Legal & General Group Plc now owns 9,168 shares of the biotechnology company’s stock worth $331,000 after buying an additional 2,583 shares in the last quarter. Finally, Virtu KCG Holdings LLC purchased a new stake in Five Prime Therapeutics during the 2nd quarter worth approximately $331,000. 83.90% of the stock is owned by institutional investors.
Shares of Five Prime Therapeutics (NASDAQ:FPRX) traded down $1.26 on Friday, reaching $25.55. The company’s stock had a trading volume of 645,800 shares, compared to its average volume of 404,694. Five Prime Therapeutics has a 12 month low of $21.41 and a 12 month high of $59.74.
WARNING: This article was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.dispatchtribunal.com/2017/12/08/brokerages-anticipate-five-prime-therapeutics-inc-fprx-will-announce-earnings-of-1-29-per-share.html.
Five Prime Therapeutics Company Profile
Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.
Get a free copy of the Zacks research report on Five Prime Therapeutics (FPRX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.